• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Hyderabad, Nov. 27

Natco Pharma Ltd (NPL) has launched Pemnat, an injectible drug used in the treatment of non-small cell lung cancer. Pemnat, to be available in 20-ml vials, would be the first launch of Pemetrexed generic version in the world, according to a company press release. Being a pre-1995 invention, Natco does not expect any litigation over the generic launch of the product. Having achieved a leadership position in the oncology (cancer studies) segment, Natco Pharma expects to improve its revenues post this launch.

Pemnat enhances the treatment options for non-small cell lung cancer. It is useful in the treatment of malignant pleural mesothelioma, in patients where curative surgery cannot be performed Pemetrexed is credited with improving survival rates, the company release said. Mesothelioma is a form of cancer where malignant cells develop in the mesothelium (a protective lining that covers the body's internal organs). Pemnat would be available at an MRP of Rs 25,500 per vial, as against the imported medicine that would cost around Rs 79,000, Natco said.

More Stories on : New Products & Services | Health | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Berlin Airport invites Indian airlines

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line